首頁 > 市場調查報告書 > 醫療設備

體外診斷

快速等離子體反應檢測 (RPR) 市場規模、佔有率和成長分析（按檢體、檢測類型、應用、最終用戶和地區分類）—2026-2033 年產業預測

市場調查報告書

商品編碼

1902355

快速等離子體反應檢測 (RPR) 市場規模、佔有率和成長分析（按檢體、檢測類型、應用、最終用戶和地區分類）—2026-2033 年產業預測

Rapid Plasma Reagin Test Market Size, Share, and Growth Analysis, By Specimen (Blood, Serum), By Test Type (Traditional Tests, Rapid Tests), By Application, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月24日 | 出版商:

SkyQuest | 英文 192 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球快速等離子體反應檢測 (RPR) 市場規模預計在 2024 年達到 30.9 億美元，從 2025 年的 34.1 億美元成長到 2033 年的 74.6 億美元，在預測期（2026-2033 年）內複合年成長率為 10.3%。

梅毒發病率的不斷上升，尤其是在男男性行為者和孕婦等高風險族群中，顯著推動了快速血漿檢測的需求。檢測技術的創新，例如自動化系統，透過簡化檢體處理和減少誤差，提高了高通量檢查室的效率。政府性行為感染感染預防的舉措，以及對能夠快速提供結果的就地檢驗的強勁需求，也推動了市場成長。此外，開發中國家對梅毒和性行為感染感染的認知不斷提高，預計也將促進銷售成長。然而，挑戰依然存在，包括資源匱乏地區難以獲得檢測服務、來自其他診斷方法的競爭、假陽性問題以及可能阻礙市場滲透的監管障礙。

全球快速血漿檢測市場促進因素

慢性病發病率的上升，以及人們健康意識的增強，顯著增加了對預防性醫療保健解決方案的需求。透過快速血漿反應（RPR）檢測進行梅毒常規篩檢，在早期發現、預防併發症和控制感染傳播方面發揮至關重要的作用。醫療保健機構正擴大將RPR檢測納入其標準預防性醫療保健實踐中，尤其是在高風險族群中。此舉有助於實現降低性行為感染傳染病發生率的整體公共衛生目標，並透過促進對高風險族群的持續篩檢，強調主動健康管理的重要性。

限制全球快速血漿反應（RPR）市場的因素

全球快速血漿溶菌酶檢測市場面臨許多限制，例如自體免疫疾病和各種感染疾病等生物因素可能導致特異性反應和不準確的檢測結果，從而需要進行額外的確認性檢測。這反過來又會延長準確診斷和治療所需的時間。這些挑戰可能會降低醫療專業人員對快速血漿溶菌酶檢測可靠性的認知，並促使他們轉向其他診斷方法。因此，這些問題可能會阻礙快速血漿溶菌酶檢測的廣泛接受和持續應用，最終影響未來的市場成長和發展。

全球快速血漿反應（RPR）市場趨勢

全球快速血漿反應 (RPR) 檢測市場正呈現出將 RPR 檢測整合到多重診斷平台中的顯著趨勢。這項創新能夠從單一檢體同時檢測多種感染疾病，例如 HIV、梅毒和肝炎，從而提高性行為感染感染 (STI)篩檢的效率。這不僅縮短了檢測時間、降低了成本，還簡化了物流流程，使其成為一種尤其在資源匱乏地區更具優勢的方法。將 RPR 檢測納入綜合檢測策略，有助於醫療機構提高診斷覆蓋率，並採用更全面的 STI 管理方法，從而推動 RPR 檢測在市場上的廣泛應用和普及。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Thermo Fisher Scientific Inc.（USA）
Danaher Corporation（USA）
Abbott Laboratories（USA）
F. Hoffmann-La Roche AG（Switzerland）
Siemens Healthineers AG（Germany）
Bio-Rad Laboratories, Inc.（USA）
Merck KGaA（Germany）
Quest Diagnostics（USA）
Cardinal Health, Inc.（USA）
bioMerieux SA（France）
Becton, Dickinson and Company（BD）（USA）
Sekisui Diagnostics（USA）
Meridian Bioscience, Inc.（USA）
Arlington Scientific Inc.（USA）
Immunostics Inc.（USA）
Novacyt Group（France）
Trinity Biotech plc（Ireland）
Atlas Medical GmbH（Germany/UK）
Sclavo Diagnostics International Srl（Italy）

結論與建議

簡介目錄

Product Code: SQMIG35D2313

Global Rapid Plasma Reagin Test Market size was valued at USD 3.09 Billion in 2024 and is poised to grow from USD 3.41 Billion in 2025 to USD 7.46 Billion by 2033, growing at a CAGR of 10.3% during the forecast period (2026-2033).

The increasing incidence of syphilis, particularly among high-risk populations like men who have sex with men and pregnant women, significantly boosts the demand for rapid plasma reagin tests. Innovations in testing technologies, such as automated systems, enhance efficiency in high-volume laboratories by streamlining sample processing and reducing errors. Government initiatives focused on STI prevention further support market growth, alongside a strong preference for point-of-care testing, which offers quick results. Additionally, rising awareness in developing countries about syphilis and STIs is expected to drive sales. However, challenges remain, including limited access in low-resource environments, competition from alternative diagnostic methods, issues with false positives, and regulatory hurdles that may hinder market penetration.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Rapid Plasma Reagin Test market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Rapid Plasma Reagin Test Market Segments Analysis

Global Rapid Plasma Reagin Test Market is segmented by Specimen, Test Type, Application, End User and region. Based on Specimen, the market is segmented into Blood, Serum and Plasma. Based on Test Type, the market is segmented into Traditional Tests and Rapid Tests. Based on Application, the market is segmented into Diagnostics and Screening. Based on End User, the market is segmented into Hospitals & Clinics, Diagnostic Laboratories and Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Rapid Plasma Reagin Test Market

The growing prevalence of chronic illnesses, along with heightened awareness around health and wellness, is driving a significant rise in the demand for preventive healthcare solutions. Routine screening for syphilis, facilitated by the Rapid Plasma Reagin (RPR) test, plays a critical role in early detection, preventing complications, and limiting the infection's spread. Healthcare providers are increasingly incorporating RPR testing into standard preventive care practices, particularly for populations at higher risk. This initiative supports overarching public health objectives aimed at lowering the incidence of sexually transmitted infections and encourages consistent screening among at-risk individuals, reinforcing the importance of proactive health management.

Restraints in the Global Rapid Plasma Reagin Test Market

The Global Rapid Plasma Reagin Test market faces limitations due to biological factors like autoimmune disorders and various infections, which may result in non-specific responses and inaccurate test outcomes. This necessitates additional confirmatory testing, consequently extending the time required for accurate diagnosis and treatment. Such challenges can undermine the perceived reliability of rapid plasma reagin tests among healthcare professionals, potentially steering them towards alternative diagnostic options. As a result, these issues may hinder the widespread acceptance and continuous utilization of rapid plasma reagin tests, ultimately impacting the growth and evolution of the market in the future.

Market Trends of the Global Rapid Plasma Reagin Test Market

The Global Rapid Plasma Reagin (RPR) Test market is witnessing a significant trend towards the integration of RPR testing with multiplex diagnostic platforms. This innovation enhances efficiency in sexually transmitted infection (STI) screening by allowing the simultaneous detection of multiple infections, such as HIV, syphilis, and hepatitis, from a single sample. The resulting reduction in testing time, costs, and logistical complexities makes this approach particularly beneficial in resource-limited settings. By embedding RPR into comprehensive testing strategies, healthcare providers can improve diagnostic coverage and adopt a holistic approach to STI management, driving the broader acceptance and utilization of RPR tests across the market.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Rapid Plasma Reagin Test Market Size by Specimen & CAGR (2026-2033)

Market Overview
Blood
Serum
Plasma

Global Rapid Plasma Reagin Test Market Size by Test Type & CAGR (2026-2033)

Market Overview
Traditional Tests
Rapid Tests

Global Rapid Plasma Reagin Test Market Size by Application & CAGR (2026-2033)

Market Overview
Diagnostics
Screening

Global Rapid Plasma Reagin Test Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals & Clinics
Diagnostic Laboratories
Research Institutes

Global Rapid Plasma Reagin Test Market Size & CAGR (2026-2033)

North America (Specimen, Test Type, Application, End User)
- US
- Canada
Europe (Specimen, Test Type, Application, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Specimen, Test Type, Application, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Specimen, Test Type, Application, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Specimen, Test Type, Application, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Thermo Fisher Scientific Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quest Diagnostics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cardinal Health, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
bioMerieux SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (BD) (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sekisui Diagnostics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Meridian Bioscience, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Arlington Scientific Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Immunostics Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novacyt Group (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Trinity Biotech plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Atlas Medical GmbH (Germany/UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sclavo Diagnostics International S.r.l. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments